NEW_CURA-LEAF_1170x120_OCT

Erez Vigodman

Teva names Kåre Schultz as new CEO

Teva names Kåre Schultz as new CEO

JERUSALEM, Israel — Kåre Schultz is joining Teva Pharmaceutical Industries Ltd. as president and chief executive officer. Teva said Monday that Schultz will take the reins from interim CEO Yitzhak Peterburg, who took on that role when Erez Vigodman stepped down as president and chief executive earlier this year. Peterburg had been Teva’s chairman but

Teva CEO Erez Vigodman steps down

Teva CEO Erez Vigodman steps down

JERUSALEM, Israel — Erez Vigodman is stepping down as president and chief executive officer of Teva Pharmaceutical Industries Ltd. Teva said late Monday that it has appointed chairman Yitzhak Peterburg as interim president and CEO, effective immediately. In addition, Teva’s board of directors has elected Sol Barer, a board member since January 2015, as chairman.

Teva announces CEO succession for generics group

Teva announces CEO succession for generics group

JERUSALEM, Israel — Dipankar Bhattacharjee has been promoted to president and chief executive officer of the Global Generic Medicines Group at Teva Pharmaceutical Industries Ltd. The appointment is effective immediately. Bhattacharjee, who has served as president and CEO of Teva Generics Europe since April 2013, succeeds Sigurdur Olafsson, who will step down from his role

Teva, Allergan complete $39 billion generics deal

Teva, Allergan complete $39 billion generics deal

NEW YORK — Teva Pharmaceutical Industries Ltd. has closed its acquisition of the Allergan plc generics business. The companies said Tuesday that under the deal, announced last July, Allergan receives $33.4 billion in cash and 100.3 million shares of Teva stock, valued at $5.4 billion based on the opening price of $53.39 for Teva shares

FTC clears Teva-Allergan, Mylan-Meda acquisitions

FTC clears Teva-Allergan, Mylan-Meda acquisitions

NEW YORK — The Federal Trade Commission has given its approval to two major pharma acquisitions: Teva Pharmaceutical Industries Ltd.’s $40 billion deal to buy Allergan plc’s generics business and Mylan N.V.’s $9.9 billion deal to acquire Meda AB. Teva said that with the FTC’s acceptance of the proposed consent order, the company has satisfied

Teva hatches plans for new global brand

JERUSALEM, Israel — Teva Pharmaceutical Industries Ltd. has begun an enterprisewide corporate identity program to build a global brand. Teva said Wednesday that it will introduce and implement the new brand within the company over the next 12 months. The company noted that it plans to unveil the brand to its 43,000 employees worldwide before

Teva to buy Allergan Generics for $40.5 billion

Teva to buy Allergan Generics for $40.5 billion

JERUSALEM — Teva Pharmaceutical Industries Ltd. plans to buy Allergan’s generic drug business for about $40.5 billion and, with the deal, has withdrawn its proposal to acquire Mylan N.V. for approximately $40 billion. Teva said Monday that Dublin, Ireland-based Allergan will receive $33.75 billion in cash and $6.75 billion in shares of Teva. The agreement

Mylan says no to Teva’s acquisition bid

POTTERS BAR, England — Mylan N.V. has rejected an unsolicited bid to be acquired by Teva Pharmaceutical Industries Ltd. in a cash-and-stock deal valued at more than $40 billion. Mylan said Monday that its board of directors unanimously voted against Teva’s offer, which was announced on April 21. Mylan stated that after a comprehensive review

Teva offers to buy Mylan in $40 billion deal

JERUSALEM — Teva Pharmaceutical Industries Ltd. has made a bid to acquire Mylan N.V. in a cash-and-stock deal valued at about $40 billion. In announcing its offer Tuesday, Teva said its proposal is a more attractive option for shareholders of Mylan, which nearly two weeks ago made an unsolicited bid to buy Perrigo Co. plc